

# Sung-Hoon Jung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4193025/publications.pdf>

Version: 2024-02-01

113  
papers

1,567  
citations

279798

23  
h-index

395702

33  
g-index

114  
all docs

114  
docs citations

114  
times ranked

2858  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. <i>British Journal of Haematology</i> , 2022, 196, 1117-1120.	2.5	2
2	Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Korean Medical Science</i> , 2022, 37, e2.	2.5	2
3	Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. <i>Blood Research</i> , 2022, 57, 51-58.	1.3	3
4	Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma. <i>Translational Oncology</i> , 2022, 20, 101413.	3.7	4
5	Update on primary plasma cell leukemia. <i>Blood Research</i> , 2022, 57, S62-S66.	1.3	7
6	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 31-45.	4.2	20
7	Adrenal insufficiency in hospitalized patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 501-503.	1.3	2
8	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
9	Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo. <i>Sensors</i> , 2021, 21, 836.	3.8	8
10	A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1599-1601.	10.5	6
11	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
12	Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1471-1485.	1.7	4
13	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
14	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trialâ€™unfit patients and subsequent therapy. <i>British Journal of Haematology</i> , 2021, 193, 101-112.	2.5	12
15	Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. <i>Blood</i> , 2021, 138, 3450-3450.	1.4	0
16	Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT. <i>Blood</i> , 2021, 138, 3757-3757.	1.4	0
17	Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population. <i>Scientific Reports</i> , 2021, 11, 22907.	3.3	3
18	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10

#	ARTICLE	IF	CITATIONS
19	Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report. <i>Electrolyte and Blood Pressure</i> , 2021, 19, 46.	1.8	3
20	Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study. <i>BioMed Research International</i> , 2021, 2021, 1-8.	1.9	3
21	Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2020, 99, 83-91.	1.8	5
22	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
23	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
24	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5
25	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
26	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
27	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Yonsei Medical Journal</i> , 2020, 61, 452.	2.2	2
28	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
29	Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 59.	2.6	11
30	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. <i>Experimental Hematology</i> , 2019, 75, 26-30.	0.4	1
31	18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 107-115.	6.4	34
32	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18
33	A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma. <i>Blood</i> , 2019, 134, 1819-1819.	1.4	2
34	Cellular immunotherapy in multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 954-965.	1.7	9
35	Clinical Impact of 18f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease. <i>Blood</i> , 2019, 134, 3142-3142.	1.4	0
36	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10

#	ARTICLE	IF	CITATIONS
37	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
38	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e529-e535.	0.4	0
39	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	4.8	49
40	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). <i>BMC Cancer</i> , 2018, 18, 729.	2.6	6
41	Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model. <i>Frontiers in Immunology</i> , 2018, 9, 1798.	4.8	32
42	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
43	Can bortezomib combined chemotherapy be helpful for even elderly unfit patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20020-e20020.	1.6	0
44	18f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 4483-4483.	1.4	0
45	Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model. <i>Blood</i> , 2018, 132, 3194-3194.	1.4	0
46	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	3.5	13
47	Immunotherapy for the treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 87-93.	4.4	33
48	Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. <i>Oncology Letters</i> , 2017, 14, 3529-3535.	1.8	2
49	Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. <i>Experimental Hematology</i> , 2017, 46, 48-55.	0.4	53
50	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. <i>Blood Research</i> , 2017, 52, 293.	1.3	23
51	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
52	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. <i>Oncotarget</i> , 2017, 8, 41538-41548.	1.8	39
53	Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. <i>Oncotarget</i> , 2017, 8, 27252-27262.	1.8	52
54	Is preoperative chronic kidney disease status associated with oncologic outcomes in upper urinary tract urothelial carcinoma? A multicenter propensity score-matched analysis. <i>Oncotarget</i> , 2017, 8, 66540-66549.	1.8	17

#	ARTICLE	IF	CITATIONS
55	The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. <i>Oncotarget</i> , 2017, 8, 66559-66568.	1.8	3
56	Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. <i>Oncotarget</i> , 2017, 8, 46047-46056.	1.8	24
57	Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. <i>Oncotarget</i> , 2017, 8, 79337-79346.	1.8	8
58	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
59	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	2.5	8
60	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4
61	Prognostic significance of platelet-lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. <i>SpringerPlus</i> , 2016, 5, 1889.	1.2	23
62	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
63	Sarcoplasmic reticulum Ca <sup>2+</sup> ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. <i>Experimental and Molecular Medicine</i> , 2016, 48, e253-e253.	7.7	15
64	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
65	Na <sup>+</sup> ve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- $\beta$ 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	3.3	36
66	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
67	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
68	Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61.	1.8	9
69	Effect of serum testosterone and percent tumor volume on extra-prostatic extension and biochemical recurrence after laparoscopic radical prostatectomy. <i>Asian Journal of Andrology</i> , 2016, 18, 54.	1.6	1
70	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	1.4	0
71	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
72	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31

#	ARTICLE	IF	CITATIONS
73	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2015, 38, 330-339.	2.4	65
74	Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. <i>Chonnam Medical Journal</i> , 2015, 51, 1.	0.9	27
75	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.9	1
76	Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment. <i>Blood Research</i> , 2015, 50, 167.	1.3	1
77	Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	2.2	33
78	Serum Lactate Dehydrogenase with a Systemic Inflammation Score Is Useful for Predicting Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 10-17.	1.4	26
79	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
80	Clinical Efficacy of Mitoxantrone and Ara-C with or without Etoposide Salvage Chemotherapy in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Retrospective Multicenter Study of the Korean Adult ALL Working Party. <i>Acta Haematologica</i> , 2015, 133, 91-97.	1.4	3
81	Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca <sup>2+</sup> transport ATPase 2 regulation. <i>Cytotherapy</i> , 2015, 17, 1421-1433.	0.7	15
82	Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
83	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 212.	1.7	27
84	5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML. <i>Blood</i> , 2015, 126, 3832-3832.	1.4	0
85	In the Novel Agents Era, Is the International Staging System Still Has the Prognostic Value in Patients with Renal Impairment?. <i>Blood</i> , 2015, 126, 5313-5313.	1.4	0
86	Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	8
87	Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. <i>International Journal of Hematology</i> , 2014, 100, 473-477.	1.6	17
88	Rapidly progressing primary splenic angiosarcoma with fatal hemorrhagic event. <i>Journal of Chemotherapy</i> , 2014, 26, 248-252.	1.5	3
89	The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	17
90	Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 389-394.	0.4	15

#	ARTICLE	IF	CITATIONS
91	Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. <i>Experimental Hematology</i> , 2014, 42, 274-281.	0.4	25
92	Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 25-32.	3.3	34
93	Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 835-840.	1.8	15
94	Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. <i>Annals of Hematology</i> , 2014, 93, 1571-1577.	1.8	3
95	Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2014, 29, 305-310.	1.3	6
96	Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. <i>International Journal of Hematology</i> , 2013, 97, 382-387.	1.6	19
97	Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. <i>International Journal of Hematology</i> , 2013, 97, 92-97.	1.6	7
98	Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. <i>Annals of Hematology</i> , 2013, 92, 789-797.	1.8	15
99	Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2013, 92, 471-479.	1.8	69
100	Class III $\beta$ -tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. <i>BMC Cancer</i> , 2013, 13, 431.	2.6	49
101	Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 774-779.	4.1	33
102	Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 74, 235.	1.8	1
103	Poor prognostic significance of <i>Mycobacterium tuberculosis</i> infection during bortezomib-containing chemotherapy in patients with multiple myeloma. <i>Blood Research</i> , 2013, 48, 35.	1.3	12
104	Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma. <i>Case Reports in Oncology</i> , 2012, 5, 413-419.	0.7	3
105	Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation. <i>Case Reports in Oncology</i> , 2012, 5, 110-113.	0.7	7
106	A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 1023-1030.	1.8	12
107	Lymphocytopenia Is Associated with an Increased Risk of Severe Infections in Patients with Multiple Myeloma Treated with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 5042-5042.	1.4	1
108	NPM1, IDH1/2 and DNMT3A Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation. <i>Blood</i> , 2012, 120, 2534-2534.	1.4	0

#	ARTICLE	IF	CITATIONS
109	A Modified Glasgow Prognostic Score (mGPS) Based On Systemic Inflammatory Response Is a Useful Indicator to Predict Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2012, 120, 5089-5089.	1.4	1
110	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in Mouse Multiple Myeloma Model. <i>Blood</i> , 2012, 120, 5010-5010.	1.4	1
111	Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma. <i>The Korean Journal of Hematology</i> , 2011, 46, 180.	0.7	3
112	Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. <i>BMC Cancer</i> , 2011, 11, 489.	2.6	69
113	Potent Immunomodulatory Drug Lenalidomide Synergistically Enhance the Effect of Dendritic Cell Vaccination on Multiple Myeloma in Mouse Model,. <i>Blood</i> , 2011, 118, 3237-3237.	1.4	0